Roche and Zealand Pharma sign $5.3 billion co-development deal for obesity treatments

Roche

Roche and Zealand Pharma agreed to co-develop and co-commercialize petrelintide, an amylin analog, both as a monotherapy and combined with Roche's CT-388 (GLP-1/GIP agonist). The deal is valued at up to $5.3 billion.

• Petrelintide targets the amylin pathway, complementing GLP-1/GIP mechanisms
• Combination designed for once-weekly dosing to maximize weight loss while optimizing tolerability
• Phase 2 ZUPREME-1 trial of petrelintide monotherapy met primary endpoint